These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 28137296

  • 1. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S, Mishra J, Gupta AK, Singh A, Shankar P, Singh S.
    Parasit Vectors; 2017 Jan 31; 10(1):49. PubMed ID: 28137296
    [Abstract] [Full Text] [Related]

  • 2. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.
    PLoS Negl Trop Dis; 2012 Jan 31; 6(5):e1657. PubMed ID: 22629478
    [Abstract] [Full Text] [Related]

  • 3. Antimony susceptible Leishmania donovani: evidence from in vitro drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.
    Ghosh S, Verma A, Kumar D, Deep DK, Ramesh V, Salotra P, Singh R.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0402623. PubMed ID: 38712926
    [Abstract] [Full Text] [Related]

  • 4. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
    Singh N, Chatterjee M, Sundar S.
    Parasit Vectors; 2014 Dec 17; 7():596. PubMed ID: 25515494
    [Abstract] [Full Text] [Related]

  • 5. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
    Seifert K, Pérez-Victoria FJ, Stettler M, Sánchez-Cañete MP, Castanys S, Gamarro F, Croft SL.
    Int J Antimicrob Agents; 2007 Sep 17; 30(3):229-35. PubMed ID: 17628445
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
    Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S.
    Am J Trop Med Hyg; 2013 Oct 17; 89(4):750-4. PubMed ID: 23980130
    [Abstract] [Full Text] [Related]

  • 8. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
    Pandey K, Ravidas V, Siddiqui NA, Sinha SK, Verma RB, Singh TP, Dhariwal AC, Das Gupta RK, Das P.
    Am J Trop Med Hyg; 2016 Nov 02; 95(5):1100-1105. PubMed ID: 27645786
    [Abstract] [Full Text] [Related]

  • 9. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
    Hendrickx S, Eberhardt E, Mondelaers A, Rijal S, Bhattarai NR, Dujardin JC, Delputte P, Cos P, Maes L.
    J Antimicrob Chemother; 2015 Nov 02; 70(11):3023-6. PubMed ID: 26253089
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
    Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, Sundar S, Ramesh V, Dujardin JC, Salotra P.
    PLoS Negl Trop Dis; 2017 Jun 02; 11(6):e0005641. PubMed ID: 28575060
    [Abstract] [Full Text] [Related]

  • 13. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
    Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M.
    PLoS One; 2014 Jun 02; 9(6):e100220. PubMed ID: 24941345
    [Abstract] [Full Text] [Related]

  • 14. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J, Madhubala R, Singh S.
    Parasitol Res; 2013 Mar 02; 112(3):1001-9. PubMed ID: 23242321
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluating drug resistance in visceral leishmaniasis: the challenges.
    Hendrickx S, Guerin PJ, Caljon G, Croft SL, Maes L.
    Parasitology; 2018 Apr 02; 145(4):453-463. PubMed ID: 27866478
    [Abstract] [Full Text] [Related]

  • 17. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
    Carnielli JBT, Crouch K, Forrester S, Silva VC, Carvalho SFG, Damasceno JD, Brown E, Dickens NJ, Costa DL, Costa CHN, Dietze R, Jeffares DC, Mottram JC.
    EBioMedicine; 2018 Oct 02; 36():83-91. PubMed ID: 30268832
    [Abstract] [Full Text] [Related]

  • 18. Drug resistance in Indian visceral leishmaniasis.
    Sundar S.
    Trop Med Int Health; 2001 Nov 02; 6(11):849-54. PubMed ID: 11703838
    [Abstract] [Full Text] [Related]

  • 19. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
    Thakur CP, Dedet JP, Narain S, Pratlong F.
    Trans R Soc Trop Med Hyg; 2001 Nov 02; 95(2):187-9. PubMed ID: 11355558
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.